ROME Therapeutics is developing therapies for cancer and autoimmune diseases by harnessing the power of the repeatome - vast stretches of uncharted genetic material that have long been dismissed as 'junk DNA'. With several drug targets identified and multiple discovery programs underway, ROME is moving to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of leaders across fields including oncology, immunology, virology, and machine learning.